Search

Displaying results 2001 - 2010 of 10000 in total
  1. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  2. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. … In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin.

  3. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol … (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH).

  4. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. … Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) [A256778] and an agonist at the parathyroid hormone type 1 (PTH1) receptor.

  5. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It i...

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.

  7. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple … (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

    Categories: Heterocyclic Compounds, 2-Ring
  8. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

    Categories: Heterocyclic Compounds, 1-Ring, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)
  9. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  10. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.